top of page

The Impact of Antimicrobial Therapy in IPF

15 months

PROGRAM TERM

Weill Cornell Medicine

ORGANIZATION

Clean-UP IPF was the first pragmatic trial in IPF that studied whether antimicrobial therapy would improve hospitalization or decrease death. Pragmatic trials are aimed at evaluating the effectiveness of treatments in real-life settings. 


The study was a collaboration with the National Heart, Lung, and Blood Institute (NHLBI), several philanthropic organizations, and a broad investigative community. While the initiation of the study was delayed, it was fully enrolled several months ahead of time with aggressive recruiting. The study was completed on October 31, 2020. 


The lead investigator was Fernando Martinez, MD Chief of the Division of Pulmonary and Critical Care Medicine and Bruce Webster, MD Professor of Medicine at the Weill Cornell Medicine, New York-Presbyterian Hospital. 


The study was recently published in the May 2021 issue of the Journal of the American Medical Association (JAMA). The PDF for the article, “Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: The CleanUP-IPF Randomized Clinical Trial” was published in the Journal of the American Medical Association (JAMA). A PDF can be found in the Publications section of this site or by clicking here. 

Breath Biopsy for Early PF Detection

Metabolic changes associated with IPF and interstitial lung abnormality (ILA) may lead to the production of unique, volatile, organic compounds (VOCs) detectable in breath.

EGCG for IPF

EGCG was discovered as an antifibrotic in pre-clinical in vivo studies and its mechanism of action blocking collagen accumulation published in 2017.

An Atlas of IPF Lung Cells

This research study was designed to identify the cellular changes that occur in the human lung cells as fibrosis develops.

Additional Programs

bottom of page